If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Pfizer inks protein degradation deal with Arvinas

Worth up to $830 million, the multi-year pact will support the discovery of multiple small molecules

by Lisa M. Jarvis
January 4, 2018 | A version of this story appeared in Volume 96, Issue 2

Schematic explaining how an Arvinas protein degrader brings together a protein and ubiquitin ligase.
Credit: Craig Crews
Arvinas designs bifunctional small molecules that prompt an unwanted protein to be tagged with ubiquitin, sending it to the cellular trash bin.

Pfizer is the latest company to get in on the swell of interest in small molecules that send problematic proteins to the cellular trash bin. The big pharma firm and Arvinas have established a multi-year protein degradation drug discovery pact worth up to $830 million.

Arvinas launched in 2013 based on technology developed in the labs of Yale University chemist Craig Crews. While conventional small molecules are typically designed to turn off or attenuate the activity of a protein, Crews came up with compounds that cause an unwanted protein to be disposed of altogether.

His bifunctional compounds, called protein-targeting chimeric molecules (Protacs), feature a protein-binding domain and a ubiquitin ligase domain. The idea is to bring a ubiquitin ligase close enough to the protein for it to be tagged for the proteasome, the cell’s trash compactor. The Protac then moves on to the next protein.

Pfizer will use Arvinas’ technology to work on proteins relevant in multiple diseases. Under the pact, the biotech firm will design molecules and Pfizer will handle their clinical development.

Pfizer joins a cluster of big firms that in the past two years have invested in protein degradation technology. Arvinas also has deals with Merck & Co. and Genentech. Another firm developing protein degraders, C4 Therapeutics, has lucrative pacts with Roche and Calico, Alphabet’s life sciences arm.

Novartis, meanwhile, is working on degraders through a collaboration with the University of California, Berkeley, and Boehringer Ingelheim has a protein degradation pact with the University of Dundee.

Since 2016, venture capital firms have put significant resources behind degraders. Arvinas has raised nearly $60 million since its launch, and C4 brought in a whopping $75 million in its first round of funding. The most recent company to emerge, Kymera Therapeutics, launched in October with $30 million in its first funding round.



This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.